-
Mashup Score: 3
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers…
Source: Investors | AgenusCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China - 4 year(s) ago
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, announced today that it has entered into an…
Source: Investors | AgenusCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 3Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer - Apr 7, 2020 - 4 year(s) ago
Press releases for Agenus
Source: Investors | AgenusCategories: Hem/OncsTweet
Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer https://t.co/ov9GaYXYzy #cancer #oncology @jbuell01 @Agenus_Bio